Pierre-Eric Juif

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 7

Top Venues

Thrombosis and haemostasis

Journal of pharmacokinetics and pharmacodynamics

Clinical and translational science

Leukemia

Idorsia Pharmaceuticals Ltd

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Idorsia Pharmaceuticals Ltd

Switzerland

Clinical Pharmacologist :: Department of Clinical Pharmacology

Publications

Todd M Bauer, Armando Santoro, Chia-Chi Lin, Ignacio Garrido-Laguna, Markus Joerger, Richard Greil, Anna Spreafico, Thomas Yau, Maria-Elisabeth Goebeler, Marie Luise Hütter-Krönke, Antonella Perotti, Pierre-Eric Juif, Darlene Lu, Louise Barys, Viviana Cremasco, Marc Pelletier, Helen Evans, Claire Fabre, Toshikiko Doi
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for immunotherapy of cancer 11 (11) (2023)
Marc-Steffen Raab, Yael C Cohen, Schjesvold Fredrik, Kimberly Aardalen, Adwait Oka, Andrew Spencer, Martin Wermke, Anita D Souza, Jonathan L Kaufman, Anna Maria Cafro, Enrique María Ocio, Noriko Doki, Kristin Henson, Gina Trabucco, Ana Carrion, Florent C Bender, Pierre-Eric Juif, Adonai Fessehatsion, Liqiong Fan, Jeffrey P Stonehouse, John W Blankenship, Brian Granda, Serena De Vita, Haihui Lu
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia (2023)
Andrea Henrich, Pierre-Eric Juif, Jasper Dingemanse, Andreas Krause
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT. Journal of pharmacokinetics and pharmacodynamics 48 (2) (2021)
Uta Schilling, Jasper Dingemanse, Michael Dobrow, Martine Baumann, Markus A Riederer, Pierre-Eric Juif, Mike Ufer
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Thrombosis and haemostasis 121 (6) (2021)
Dominik Lott, Pierre-Eric Juif, Jasper Dingemanse, Andreas Krause
Modelling pharmacokinetics and pharmacodynamics of the selective S1P1 receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients. British journal of clinical pharmacology 86 (4) (2020)
Pierre-Eric Juif, Jasper Dingemanse, Peter Winkle, Mike Ufer
Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P1 R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects. Clinical and translational science 14 (1) (2020)
Margaux Boehler, Pierre-Eric Juif, Matthias Hoch, Jasper Dingemanse
Absolute Bioavailability of Ponesimod, a Selective S1P1 Receptor Modulator, in Healthy Male Subjects. European journal of drug metabolism and pharmacokinetics 42 (1) (2017)

Pierre-Eric Juif.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Pierre-Eric Juif